Shanghai Kehua Bio-Engineering (002022.SZ) stated on the investor platform that the company adopts a sales model which focuses on dealers while also utilizing direct sales for both self-produced and third-party products. In order to adapt to the development trend of the in-vitro diagnostic industry and in consideration of the structural characteristics of in-vitro diagnostic products, the company has built an extensive network of dealers both domestically and abroad, and possesses a professional marketing team and a sound marketing system. The company does not currently have a store on any e-commerce platform.
科华生物(002022.SZ)：公司自产产品、代理产品均采用“经销为主、直销为辅”的销售模式
Shanghai Kehua Bio-Engineering (002022.SZ): Both the company's self-produced products and agent products adopt a sales model mainly based on distribution and supplemented by direct sales.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.